BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 25666183)

  • 1. Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.
    Bilen MA; Fu S; Falchook GS; Ng CS; Wheler JJ; Abdelrahim M; Erguvan-Dogan B; Hong DS; Tsimberidou AM; Kurzrock R; Naing A
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):869-74. PubMed ID: 25666183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.
    Said R; Kakadiaris E; Piha-Paul S; Fu S; Falchook G; Janku F; Wheler JJ; Zinner R; Hong DS; Kurzrock R; Tsimberidou AM
    Cancer Chemother Pharmacol; 2016 May; 77(5):1097-102. PubMed ID: 27085994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer.
    Said R; Ye Y; Hong DS; Naing A; Falchook G; Fu S; Wheler JJ; Piha-Paul S; Tsimberidou AM
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):575-81. PubMed ID: 26825327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
    Münster P; Marchion D; Bicaku E; Schmitt M; Lee JH; DeConti R; Simon G; Fishman M; Minton S; Garrett C; Chiappori A; Lush R; Sullivan D; Daud A
    J Clin Oncol; 2007 May; 25(15):1979-85. PubMed ID: 17513804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma.
    Tufail M; Siegel DS; McBride L; Bilotti E; Bello E; Anand P; Olivo K; Bendarz U; McNeill A; Vesole DH
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):186-90. PubMed ID: 22381702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.
    Ullenhag GJ; Rossmann E; Liljefors M
    PLoS One; 2015; 10(4):e0121197. PubMed ID: 25837499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial.
    Atmaca A; Al-Batran SE; Maurer A; Neumann A; Heinzel T; Hentsch B; Schwarz SE; Hövelmann S; Göttlicher M; Knuth A; Jäger E
    Br J Cancer; 2007 Jul; 97(2):177-82. PubMed ID: 17579623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of pomalidomide given for patients with advanced solid tumors.
    Cooney MM; Nock C; Bokar J; Krishnamurthi S; Gibbons J; Rodal MB; Ness A; Remick SC; Dreicer R; Dowlati A
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):755-61. PubMed ID: 22875080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.
    Ganesan P; Piha-Paul S; Naing A; Falchook G; Wheler J; Fu S; Hong DS; Kurzrock R; Janku F; Laday S; Bedikian AY; Kies M; Wolff RA; Tsimberidou AM
    Invest New Drugs; 2014 Apr; 32(2):279-86. PubMed ID: 23756764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.
    Ganesan P; Piha-Paul S; Naing A; Falchook G; Wheler J; Janku F; Zinner R; Laday S; Kies M; Tsimberidou AM
    Invest New Drugs; 2013 Dec; 31(6):1505-13. PubMed ID: 23982248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
    Daud AI; Dawson J; DeConti RC; Bicaku E; Marchion D; Bastien S; Hausheer FA; Lush R; Neuger A; Sullivan DM; Munster PN
    Clin Cancer Res; 2009 Apr; 15(7):2479-87. PubMed ID: 19318485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy.
    Hwu WJ; Knight RD; Patnana M; Bassett R; Papadopoulos NE; Kim KB; Hwu P; Bedikian A
    Melanoma Res; 2010 Dec; 20(6):501-6. PubMed ID: 20859231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors.
    Fury MG; Sherman E; Haque S; Korte S; Lisa D; Shen R; Wu N; Pfister D
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):591-8. PubMed ID: 21913034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial.
    Hitz F; Fischer N; Pabst T; Caspar C; Berthod G; Eckhardt K; Berardi Vilei S; Zucca E; Mey U;
    Ann Hematol; 2013 Aug; 92(8):1033-40. PubMed ID: 23592273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.
    Pönisch W; Heyn S; Beck J; Wagner I; Mohren M; Hoffmann FA; Lange T; Schmalfeld M; Zehrfeld T; Schwarzer A; Winkelmann C; Edelmann T; Röhrborn R; Hebenstreit K; Al-Ali HK; Jäkel N; Niederwieser D
    Br J Haematol; 2013 Jul; 162(2):202-9. PubMed ID: 23692564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
    Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
    Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
    Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
    Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.
    Chow LQ; Jonker DI; Dy GK; Nicholas G; Fortin C; Patricia D; Adjei AA; Belani CP; Gupta A; Park JS; Zhang S; Sbar EI; Laurie SA
    Cancer Chemother Pharmacol; 2013 May; 71(5):1273-85. PubMed ID: 23468081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors.
    Kalmadi S; Davis M; Dowlati A; O'Keefe S; Cline-Burkhardt M; Pelley RJ; Borden E; Dreicer R; Bukowski R; Mekhail T
    Invest New Drugs; 2007 Jun; 25(3):211-6. PubMed ID: 17103043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.